Related Experiment Video
Updated: Aug 13, 2026
08:28
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Severe iatrogenic ergotism: incidence and clinical importance
1Department of Medicine, University Hospital, Geneva.
VASA. Zeitschrift Fur Gefasskrankheiten
|January 1, 1991
Summary
Severe vasospasm from ergot derivatives can cause limb ischemia but is treatable with vasodilators. Close monitoring of patients using ergot medications is crucial to prevent severe complications.
Area of Science:
- Vascular Medicine
- Pharmacology
- Toxicology
Background:
- Ergot derivatives are common treatments for migraine and deep vein thrombosis prevention.
- Severe vasospasm is a rare but serious adverse effect of ergot derivative use.
Purpose of the Study:
- To report on the incidence and management of severe extremity vasospasm caused by ergot derivatives.
- To evaluate the efficacy of sodium nitroprusside in treating ergot-induced vasospasm.
Main Methods:
- Retrospective case series of 7 patients admitted for severe extremity vasospasm.
- Treatment involved intravenous vasodilator drugs, primarily sodium nitroprusside.
- Hemodynamic monitoring included ankle-brachial index and toe-arm systolic pressure.
Main Results:
- Seven patients experienced severe limb ischemia due to ergotamine tartrate or dihydroergotamine-heparin.
- Intravenous sodium nitroprusside successfully treated vasospasm in 6 out of 7 patients.
- No amputations were required in this series, though two patients developed distal necrosis.
Conclusions:
- Severe ergotism incidence is low (<0.5/100,000/year), contrasting with higher subclinical ergotism rates.
- Early recognition and vasodilator treatment of ergot-induced vasospasm can prevent limb loss.
- Patients on ergot derivatives require close monitoring for potential severe vasospasm.
Related Concept Videos
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...